FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989265170> ?p ?o ?g. }

• W2989265170 endingPage "1282" @default.
• W2989265170 startingPage "1282" @default.
• W2989265170 abstract "Objective: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults. Altered mitochondrial metabolism has been shown to be involved in the pathogenesis of CLL. Ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK), and venetoclax, an inhibitor of B-cell lymphoma 2 (Bcl-2) protein are approved therapies for CLL. The adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) signaling axis senses the metabolic demands of cells and regulates mitochondrial function. Silent information regulator T1 (SIRT1) is a cytoplasmic enzyme that mediates NAD+-dependent deacetylation of target substrates. The importance of BTK, AKT, and AMPK/SIRT/PGC-1α signaling pathway have to be explored yet in CLL. Ibrutinib and venetoclax may trigger a switching off of AMPK and /or SIRT1 signaling leading to impaired PGC-1α expression/activity and diminished mitochondrial activity. The effects of these drugs on mitochondrial bioenergetics profile, cell viability, mitochondrial membrane potential (MMP), reactive oxygen species (ROS) and protein levels of p-BTK, p-AKT, Bcl-2, p-AMPK, SIRT1, and PGC-1α were analyzed. We hypothesize that ibrutinib, along with venetoclax, will alter CLL mitochondrial bioenergetics profiles and function, cell viability, and ROS levels through the involvement of BTK, AKT and AMPK/SIRT/PGC-1α signaling pathway and enable lower doses and profound effects for combination therapies rather than single agent therapy. Methods: The high resolution Oroboros Oxygraph 2K (Oroboros Instruments, Austria), a Clarke-type oxygen electrode, is used to measure mitochondrial respiration rates of CLL cells at 370C. Freshly isolated CLL cells (10 mil. cells/ml) were added to the chamber in 2 ml of RPMI. After the measurement of basal respiration rates, the following chemicals were added: oligomycin (2uM), FCCP: carbonylcyanide p-trifluoromethoxyphenylhydrazone (2-12 uM), and antimycin A (2 uM). Oxygen consumption rate is expressed in pmol oxygen/s /mil. cells. Protein levels in CLL cell lysates were determined by Western blotting. Cell viability, MMP, and ROS were assessed by the flow cytometer (NovoCyte). Results: CLL cells obtained ex vivo from ibrutinib treated patients had decreased mitochondrial bioenergetics compared to pre-treatment samples. Primary CLL cells treated in vitro with sub-lethal doses of ibrutinib for 24 or 48h showed significantly decreased basal respiration rates, maximal respiration rates, and spare respiratory capacity compared to DMSO vehicle control. These parameters were also significantly affected by low doses (0.5 - 2 nM) of venetoclax. The combination treatment of ibrutinib with venetoclax for 24 or 48h significantly decreased these bioenergetics parameters compared to each individual drug alone except for the spare respiratory capacity vs venetoclax alone at 24 h. MMP was significantly decreased by these drug treatments and its combinations compared to DMSO. Cell viability was used to confirm a sub-lethal phenotype. ROS levels were significantly increased by venetoclax compared to DMSO, and in combination with ibrutinib vs ibrutinib alone. However, ROS levels by ibrutinib were not significantly changed compared to DMSO or venetoclax. Protein levels of p-BTK, p-AKT, p-AMPK, SIRT1, and PGC-1α were decreased by ibrutinib or venetoclax alone compared to DMSO and further decreased by the combination of these two drugs compared to single agent. Conclusion: CLL cells from ibrutinib treated patients, a clinically approved BTK inhibitor, demonstrated decreased bioenergetics similar to normal B-lymphocytes suggesting ibrutinib treatment normalizes the mitochondrial bioenergetics in CLL. Ibrutinib and venetoclax affected bioenergetics profiles in CLL cells at low doses. The combined effect of these drugs on the mitochondrial bioenergetics profiles and cell viability is more profound than each BTK or Bcl-2 inhibitor agent alone. Protein levels of p-BTK, p-AKT, p-AMPK, SIRT1, and PGC-1α in ibrutinib and venetoclax treated samples were reduced compared to DMSO and each single agent inhibitor. These novel data suggest the involvement of BTK, AKT and AMPK/SIRT/PGC-1α signaling pathway to target mitochondrial metabolism and provide rational therapeutic combinations that may lead to reduced toxicity and increased drug efficacy in CLL. Disclosures Johnston: Janssen: Research Funding. Banerji:Janssen: Consultancy, Honoraria, Research Funding; Roche: Honoraria, Licensing fee, Research Funding; Abbvie: Consultancy, Honoraria; CIHR: Research Funding; LLSC: Research Funding; Research Manitoba: Research Funding; Astra-Zeneca: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Research Funding; Dana-Farber Cancer Institute: Other: Licencing fee; CCMF: Research Funding; CancerCare Manitoba/University of Manitoba: Employment; CAPhO: Honoraria; BIOGEN: Other: Licensing fee." @default.
• W2989265170 created "2019-11-22" @default.
• W2989265170 creator A5004829406 @default.
• W2989265170 creator A5008948746 @default.
• W2989265170 creator A5015319915 @default.
• W2989265170 creator A5030453913 @default.
• W2989265170 creator A5036736992 @default.
• W2989265170 creator A5061828646 @default.
• W2989265170 creator A5065584166 @default.
• W2989265170 date "2019-11-13" @default.
• W2989265170 modified "2023-09-30" @default.
• W2989265170 title "Ibrutinib in Combination with Venetoclax Decreases Mitochondrial Bioenergetics through the Impaired BTK, AKT and AMPK/SIRT/PGC-1α Signaling Pathway in CLL" @default.
• W2989265170 doi "https://doi.org/10.1182/blood-2019-127562" @default.
• W2989265170 hasPublicationYear "2019" @default.
• W2989265170 type Work @default.
• W2989265170 sameAs 2989265170 @default.
• W2989265170 citedByCount "1" @default.
• W2989265170 countsByYear W29892651702022 @default.
• W2989265170 crossrefType "journal-article" @default.
• W2989265170 hasAuthorship W2989265170A5004829406 @default.
• W2989265170 hasAuthorship W2989265170A5008948746 @default.
• W2989265170 hasAuthorship W2989265170A5015319915 @default.
• W2989265170 hasAuthorship W2989265170A5030453913 @default.
• W2989265170 hasAuthorship W2989265170A5036736992 @default.
• W2989265170 hasAuthorship W2989265170A5061828646 @default.
• W2989265170 hasAuthorship W2989265170A5065584166 @default.
• W2989265170 hasConcept C11960822 @default.
• W2989265170 hasConcept C203014093 @default.
• W2989265170 hasConcept C2776780712 @default.
• W2989265170 hasConcept C2777938653 @default.
• W2989265170 hasConcept C2778461978 @default.
• W2989265170 hasConcept C2779675984 @default.
• W2989265170 hasConcept C2779878957 @default.
• W2989265170 hasConcept C2780124434 @default.
• W2989265170 hasConcept C42362537 @default.
• W2989265170 hasConcept C502942594 @default.
• W2989265170 hasConcept C62478195 @default.
• W2989265170 hasConcept C75217442 @default.
• W2989265170 hasConcept C86803240 @default.
• W2989265170 hasConcept C90059517 @default.
• W2989265170 hasConcept C95444343 @default.
• W2989265170 hasConcept C97029542 @default.
• W2989265170 hasConceptScore W2989265170C11960822 @default.
• W2989265170 hasConceptScore W2989265170C203014093 @default.
• W2989265170 hasConceptScore W2989265170C2776780712 @default.
• W2989265170 hasConceptScore W2989265170C2777938653 @default.
• W2989265170 hasConceptScore W2989265170C2778461978 @default.
• W2989265170 hasConceptScore W2989265170C2779675984 @default.
• W2989265170 hasConceptScore W2989265170C2779878957 @default.
• W2989265170 hasConceptScore W2989265170C2780124434 @default.
• W2989265170 hasConceptScore W2989265170C42362537 @default.
• W2989265170 hasConceptScore W2989265170C502942594 @default.
• W2989265170 hasConceptScore W2989265170C62478195 @default.
• W2989265170 hasConceptScore W2989265170C75217442 @default.
• W2989265170 hasConceptScore W2989265170C86803240 @default.
• W2989265170 hasConceptScore W2989265170C90059517 @default.
• W2989265170 hasConceptScore W2989265170C95444343 @default.
• W2989265170 hasConceptScore W2989265170C97029542 @default.
• W2989265170 hasIssue "Supplement_1" @default.
• W2989265170 hasLocation W29892651701 @default.
• W2989265170 hasOpenAccess W2989265170 @default.
• W2989265170 hasPrimaryLocation W29892651701 @default.
• W2989265170 hasRelatedWork W2577781255 @default.
• W2989265170 hasRelatedWork W2989265170 @default.
• W2989265170 hasRelatedWork W3013993168 @default.
• W2989265170 hasRelatedWork W3133529143 @default.
• W2989265170 hasRelatedWork W3139147523 @default.
• W2989265170 hasRelatedWork W3203396887 @default.
• W2989265170 hasRelatedWork W4223947293 @default.
• W2989265170 hasRelatedWork W4225515604 @default.
• W2989265170 hasRelatedWork W4291016358 @default.
• W2989265170 hasRelatedWork W4309187738 @default.
• W2989265170 hasVolume "134" @default.
• W2989265170 isParatext "false" @default.
• W2989265170 isRetracted "false" @default.
• W2989265170 magId "2989265170" @default.
• W2989265170 workType "article" @default.